3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
38
Breast Neoplasms
31
Lung Neoplasms
25
Colorectal Neoplasms
15
Prostatic Neoplasms
13
Pancreatic Neoplasms
11
Ovarian Neoplasms
11
Head and Neck Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Sarcoma
8
Colonic Neoplasms
8
Uterine Cervical Neoplasms
7
Melanoma
7
Glioma
7
Esophageal Neoplasms
7
Carcinoma, Hepatocellular
7
Lymphoma
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neoplastic Cells, Circulating
5
Multiple Myeloma
5
Endometrial Neoplasms
5
Brain Neoplasms
5
Neoplasm, Residual
4
Gastrointestinal Neoplasms
4
Carcinoma, Squamous Cell
4
Carcinoma, Renal Cell
4
Adenocarcinoma
4
Thrombosis
3
Skin Neoplasms
3
Interventions
darolutamide
3
Pluvicto
3
Docetaxel
3
testosterone 17 beta-cypionate
2
sipuleucel-T
1
lactitol
1
fludarabine phosphate
1
fludarabine
1
enzalutamide
1
ebastine
1
cabozantinib
1
cabazitaxel
1
Standard of Care
1
Prednisone
1
Prednisolone
1
PSMA-617
1
Gonadotropin-Releasing Hormone
1
Cyclophosphamide
1
Bortezomib
1
Blood Specimen Collection
1
Androgen Antagonists
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-resistant Prostate Cancer
×
Blood Specimen Collection
×
Clear all
NCT06492122
2026-05-26
ProTACT
Full-Life Technologies GmbH
Phase 1
Recruiting
50 enrolled